PMID- 33665047
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231110
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 13
IP  - 1
DP  - 2021 Jan 30
TI  - Real-World Observational Study of Glimepiride and Metformin Fixed-Dose 
      Combination Along With Insulin in the Management of Type 2 Diabetes Mellitus: 
      Indian Experience.
PG  - e13020
LID - 10.7759/cureus.13020 [doi]
LID - e13020
AB  - Background Type 2 diabetes mellitus (T2DM) is associated with a significant 
      burden on both patients and the healthcare system. This study aimed to evaluate 
      the demographics of patients with T2DM receiving different strengths of 
      glimepiride and metformin combination along with insulin. This study also 
      examined the concomitant conditions and therapies, duration of therapies, dosage 
      titration, glycated hemoglobin (HbA1c) levels, hypoglycemic events, and weight 
      changes during the course of therapy. Methods This retrospective, multicenter 
      (347), observational study included adult patients with T2DM who received 
      glimepiride and metformin combination along with insulin. Data related to 
      demographic characteristics, duration of disease, co-morbidities, concomitant 
      medications, and dosage pattern was collected from medical records authenticated 
      by physicians during routine care. Results A total of 7058 patients were included 
      in the study. The median age of included patients was 55 years and around 29% 
      were aged >60 years and 60% were men. The majority of patients (83.3%) had 
      insulin treatment initiation after glimepiride and metformin combination while 
      other patients (16.7%) received glimepiride and metformin combination after 
      insulin initiation. The mean HbA1c levels significantly decreased with a mean 
      change of 1.33%. In one-third of the patients, down-titration of the insulin dose 
      was done, indicating the insulin-sparing effect with the addition of the 
      glimepiride and metformin combination. The most common comorbid condition was 
      hypertension (64.7%). Of 3705 patients, 33.2% patients had weight loss and 66.8% 
      had weight gain. A total of 432 patients reported hypoglycemic events. Physician 
      global evaluation of efficacy and tolerability showed a good to excellent on the 
      scale (97.3% and 96.6%). Conclusion This study presented good HbA1c lowering with 
      glimepiride and metformin combination with insulin, ensuring a positive clinical 
      outcome. Good to excellent efficacy and tolerability were observed in patients 
      with T2DM across the age groups, in early as well as long-standing disease.
CI  - Copyright (c) 2021, Prasanna Kumar et al.
FAU - Prasanna Kumar, K M
AU  - Prasanna Kumar KM
AD  - Department of Endocrinology, Center for Diabetes and Endocrine Care, Bengaluru, 
      IND.
FAU - Seshadri, Krishna
AU  - Seshadri K
AD  - Department of Endocrinology, Apollo Speciality Hospital, Chennai, IND.
FAU - Aravind, S R
AU  - Aravind SR
AD  - Department of Diabetology, Diacon Hospital, Bengaluru, IND.
FAU - Deb, Prasun
AU  - Deb P
AD  - Department of Endocrinology, Krishna Institute of Medical Sciences (KIMS) 
      Hospital, Hyderabad, IND.
FAU - Modi, K D
AU  - Modi KD
AD  - Department of Endocrinology, CARE Hospital, Hyderabad, IND.
FAU - Gopal, Raju A
AU  - Gopal RA
AD  - Department of Endocrinology, Endodiab Clinic, Kozhikode, IND.
FAU - G, Vijaya Kumar
AU  - G VK
AD  - Department of Diabetology, Diabetes Medicare Centre, Chennai, IND.
FAU - Moses, Cr Anand
AU  - Moses CA
AD  - Department of Diabetology, Moses Diabetes and Medical Centre, Chennai, IND.
FAU - Abhyankar, Mahesh
AU  - Abhyankar M
AD  - Scientific Services, USV Private Limited, Mumbai, IND.
FAU - Revenkar, Santosh
AU  - Revenkar S
AD  - Scientific Services, USV Private Limited, Mumbai, IND.
LA  - eng
PT  - Journal Article
DEP - 20210130
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7920844
OTO - NOTNLM
OT  - diabetes
OT  - dosage up titration
OT  - hba1c
OT  - hypoglycemic
OT  - tolerability
COIS- The authors have declared financial relationships, which are detailed in the next 
      section.
EDAT- 2021/03/06 06:00
MHDA- 2021/03/06 06:01
PMCR- 2021/01/30
CRDT- 2021/03/05 06:07
PHST- 2021/03/05 06:07 [entrez]
PHST- 2021/03/06 06:00 [pubmed]
PHST- 2021/03/06 06:01 [medline]
PHST- 2021/01/30 00:00 [pmc-release]
AID - 10.7759/cureus.13020 [doi]
PST - epublish
SO  - Cureus. 2021 Jan 30;13(1):e13020. doi: 10.7759/cureus.13020.